The study herein is the first to describe a role of AXL in resistance to docetaxel both in vitro and in vivo, and thus, provides a rationale for the development and use of anti-AXL therapeutics for the treatment of docetaxel-resistant prostate cancer. The gene discussed is AXL; the disease is prostate carcinoma.